^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Neuroendocrine Tumor

    No biomarker
    Neuroendocrine Tumor
    surufatinib
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    sunitinib
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    everolimus
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    lanreotide prolonged-release subcutaneous
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    sunitinib
    Sensitive
    :
    A1
    VHL mutation
    Neuroendocrine Tumor
    belzutifan
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    EP
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    octreotide
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    temozolomide
    Sensitive
    :
    A2
    SSTR positive
    Neuroendocrine Tumor
    lanreotide prolonged-release subcutaneous
    Sensitive
    :
    A2
    SSTR positive
    Neuroendocrine Tumor
    octreotide
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FOLFOX
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    carboplatin + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    temozolomide + capecitabine
    Sensitive
    :
    A2
    MSI-H/dMMR
    Neuroendocrine Tumor
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    oxaliplatin
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    dacarbazine
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    cisplatin + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    nivolumab + ipilimumab
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FOLFIRINOX
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    carboplatin + irinotecan
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    cisplatin + irinotecan
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FOLFIRI
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    CAPOX
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    5-fluorouracil + streptozocin
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    doxorubicin hydrochloride + streptozocin
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    streptozocin
    Sensitive
    :
    A2
    TMB-H
    Neuroendocrine Tumor
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FAS
    Sensitive
    :
    A2